Cosmos Health, Inc.

Cosmos Health, Inc. is considered overvalued and risky due to negative valuation ratios and poor long-term performance, despite a strong year-to-date return of 39.30% compared to the S&P 500's 12.22%.

As of May 18, 2016, Cosmos Health, Inc. is considered overvalued and risky due to significant financial challenges, negative performance indicators, and a year-to-date return of -37.16%, underperforming relative to peers and the S&P 500.

As of June 11, 2025, Cosmos Health, Inc. exhibits a neutral technical stance with mixed indicators, showing mild bullish momentum from the MACD and KST but bearish signals from Bollinger Bands and moving averages, resulting in a lack of clear trend direction.

Cosmos Health, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $14 million and a net profit of -$1 million. It has a market cap of $12.40 million and key metrics indicating a loss-making status.

As of Jun 18, Cosmos Health, Inc. has a market capitalization of 12.40 million, with net sales of 53.55 million and a net profit of -15.13 million over the latest four quarters. Shareholder's funds are reported at 24.53 million, and total assets amount to 54.31 million.